Many healthcare providers mistakenly believe that novel glucose-lowering drugs, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, are the adequate or even ultimate solution for patients with T2DM and CKD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.